SecBot SecBot
6-K ·Filed Jun 26, 2026

RDY

DR REDDYS LABORATORIES LTD
BEARISH
Impact 5/10
Horizonweeks Processed4mo ago SEC0001575872-26-000444
Notable filing: 6-K
Actionable Insight ▼ Bearish

Monitor for subsequent FDA communications (warning letter or close-out notice) and the company's detailed response to observations. The stock may see modest negative pressure near-term given regulatory overhang, but the lack of escalation to a warning letter suggests limited immediate disruption. Longer-term, resolution of observations is key for biologics pipeline progress.

DirectionBearish
Confidencemedium
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$15.38
T+0 close · Jun 26, 2026 · via day close
Latest settled
−23.28%
T+20 · $11.80
Vs SPY
−24.54%
α at T+20
Next horizon
T+60
due 8w ago
  1. T+0 · Jun 26 $15.38entry
  2. T+1 · 5mo ago −3.38%α −5.03% · $14.86
  3. T+5 · 4mo ago −6.50%α −8.67% · $14.38
  4. T+20 · 4mo ago −23.28%α −24.54% · $11.80
  5. T+60 · due 8w ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dr. Reddy's received a Form 483 with seven observations from the USFDA following a Pre-License Inspection at its biologics manufacturing facility in Bachupally, Hyderabad (June 16-25, 2026). The company will respond within the stipulated timeline, but the observations raise compliance concerns that could delay future product approvals. This follows prior inspection-related disclosures in 2023 and 2025, suggesting ongoing regulatory scrutiny.

Key Facts

  • USFDA completed a Pre-License Inspection (PLI) at Dr. Reddy's biologics facility in Bachupally, Hyderabad, from June 16 to June 25, 2026.
  • The company was issued a Form 483 with seven observations, which it will address within the stipulated timeline.
  • The filing references earlier inspection disclosures on October 12, 2023 and September 13, 2025, indicating a history of regulatory attention at this site.
  • No financial impact, warning letter, or product-specific impact is disclosed in the filing.

Financial Impact

Undisclosed; potential delays in biologics license approvals could affect future revenue streams, but no quantification provided.

future_revenueregulatory_approval_timelinecompliance_costs

Risk Factors

  • FDA may escalate with a warning letter or other enforcement action if responses are insufficient.
  • Delays in biologics product approvals could reduce expected future revenues from this facility.
  • Negative sentiment may weigh on the stock until observations are resolved.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
52% bullish (44 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000444
Document: 0001575872-26-000444-index.html0001575872-26-000444
Document: 0001575872-26-000444.txt0001575872-26-000444

Track record

73 reports on RDY

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +13.92% at T+60 after the Aug 3, 2026 report. 6 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
  2. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
  3. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
  4. Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
  5. Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
  6. Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
  7. Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  8. Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
  10. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 26, 2026